Company
Evotec SE
Headquarters: Hamburg, Germany
Employees: 4,081
CEO: Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
Market Cap
€1.71 Billion
EUR as of July 1, 2024
US$1.84 Billion
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health. It has collaboration agreements with Bayer AG; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Celgene; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Evotec SE has the following listings and related stock indices.
Stock: FSX: EVT wb_incandescent
Stock: FSX: EVTA wb_incandescent
Stock: XETR: EVTA wb_incandescent
Stock: XETR: EVT wb_incandescent
Stock: OTC: EVOTF wb_incandescent
Stock: OTC: EVTCY wb_incandescent